Pfizer's Allergan deal teeters on new U.S. inversion curbs

April 5, 2016 11:59 PM

59 0

NEW YORK U.S. drug maker Pfizer Inc's $160 billion agreement to acquire Botox maker Allergan Plc was on the brink of being abandoned on Tuesday, after the U.S. Treasury issued new rules on how tax "inversion" deals can be structured.

Allergan's shares were hit considerably hard on Tuesday, showing how the rules that were issued on Monday targeted the biggest inversion attempted to date. The federal government has grappled with a wave of recent inversions by U.S. companies seeking to slash their tax bills by redomiciling overseas...

Also read: China's app for everything files for huge Hong Kong IPO

Read more

To category page